Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study | Zendy

Mario Salvi | Zendy; Guia Vannucchi | Zendy; Irene Campi | Zendy; Nicola Currò | Zendy; Davide Dazzi | Zendy; Simona Simonetta | Zendy; P. Bonara | Zendy; Stefania Rossi | Zendy; C. Sina | Zendy; Claudio Guastella | Zendy; Roberto Ratiglia | Zendy; Paolo BeckPeccoz | Zendy

Open Access

Treatment of Graves’ disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study

Author(s) -

Mario Salvi,

Guia Vannucchi,

Irene Campi,

Nicola Currò,

Davide Dazzi,

Simona Simonetta,

P. Bonara,

Stefania Rossi,

C. Sina,

Claudio Guastella,

Roberto Ratiglia,

Paolo BeckPeccoz

Publication year - 2007

Publication title -

european journal of endocrinology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.897

H-Index - 148

eISSN - 1479-683X

pISSN - 0804-4643

DOI - 10.1530/eje.1.02325

Subject(s) - medicine , rituximab , cd20 , gastroenterology , trab , endocrinology , graves' ophthalmopathy , graves' disease , thyroid , antibody , thyroid function , ofatumumab , immunology , lymphoma

Hyperthyroid Graves' disease (GD) is a B-cell-mediated condition caused by TSH receptor antibodies (TRAb), which decline when GD remits. Anti-CD20 monoclonal antibody rituximab (RTX) induces transient B-cell depletion that may potentially modify the active inflammatory phase of thyroid-associated ophthalmopathy (TAO).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research